168 related articles for article (PubMed ID: 26226403)
1. Brain Targeting of a Water Insoluble Antipsychotic Drug Haloperidol via the Intranasal Route Using PAMAM Dendrimer.
Katare YK; Daya RP; Sookram Gray C; Luckham RE; Bhandari J; Chauhan AS; Mishra RK
Mol Pharm; 2015 Sep; 12(9):3380-8. PubMed ID: 26226403
[TBL] [Abstract][Full Text] [Related]
2. Intranasal haloperidol-loaded miniemulsions for brain targeting: Evaluation of locomotor suppression and in-vivo biodistribution.
El-Setouhy DA; Ibrahim AB; Amin MM; Khowessah OM; Elzanfaly ES
Eur J Pharm Sci; 2016 Sep; 92():244-54. PubMed ID: 27154259
[TBL] [Abstract][Full Text] [Related]
3. Dendrimer nanotechnology for enhanced formulation and controlled delivery of resveratrol.
Chauhan AS
Ann N Y Acad Sci; 2015 Aug; 1348(1):134-40. PubMed ID: 26173478
[TBL] [Abstract][Full Text] [Related]
4. Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting.
Shah B; Khunt D; Misra M; Padh H
Pharm Res; 2018 Jan; 35(1):8. PubMed ID: 29294189
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs.
Mignani S; Shi X; Karpus A; Majoral JP
Eur J Med Chem; 2021 Jan; 209():112905. PubMed ID: 33069435
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: Formulation, physicochemical and pharmacokinetic consideration.
Shah B; Khunt D; Misra M; Padh H
Eur J Pharm Sci; 2016 Aug; 91():196-207. PubMed ID: 27174656
[TBL] [Abstract][Full Text] [Related]
7. Polyamidomine dendrimers: an excellent drug carrier for improving the solubility and bioavailability of puerarin.
Gu L; Wu Zh; Qi X; He H; Ma X; Chou X; Wen X; Zhang M; Jiao F
Pharm Dev Technol; 2013; 18(5):1051-7. PubMed ID: 22303809
[TBL] [Abstract][Full Text] [Related]
8. PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization.
Nasr M; Najlah M; D'Emanuele A; Elhissi A
Int J Pharm; 2014 Jan; 461(1-2):242-50. PubMed ID: 24275446
[TBL] [Abstract][Full Text] [Related]
9. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route.
Patel S; Chavhan S; Soni H; Babbar AK; Mathur R; Mishra AK; Sawant K
J Drug Target; 2011 Jul; 19(6):468-74. PubMed ID: 20958095
[TBL] [Abstract][Full Text] [Related]
10. Intranasal administration of brain-targeted HP-β-CD/chitosan nanoparticles for delivery of scutellarin, a compound with protective effect in cerebral ischaemia.
Liu S; Ho PC
J Pharm Pharmacol; 2017 Nov; 69(11):1495-1501. PubMed ID: 28809432
[TBL] [Abstract][Full Text] [Related]
11. Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin.
Durairaj C; Kadam RS; Chandler JW; Hutcherson SL; Kompella UB
Invest Ophthalmol Vis Sci; 2010 Nov; 51(11):5804-16. PubMed ID: 20484584
[TBL] [Abstract][Full Text] [Related]
12. Optimization and in vitro toxicity evaluation of G4 PAMAM dendrimer-risperidone complexes.
Prieto MJ; Temprana CF; del Río Zabala NE; Marotta CH; Alonso Sdel V
Eur J Med Chem; 2011 Mar; 46(3):845-50. PubMed ID: 21251731
[TBL] [Abstract][Full Text] [Related]
13. Dendrimers for Drug Delivery.
Chauhan AS
Molecules; 2018 Apr; 23(4):. PubMed ID: 29670005
[TBL] [Abstract][Full Text] [Related]
14. All-atomistic molecular dynamics (AA-MD) studies and pharmacokinetic performance of PAMAM-dendrimer-furosemide delivery systems.
Otto DP; de Villiers MM
Int J Pharm; 2018 Aug; 547(1-2):545-555. PubMed ID: 29908331
[TBL] [Abstract][Full Text] [Related]
15. Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system.
Ke W; Zhao Y; Huang R; Jiang C; Pei Y
J Pharm Sci; 2008 Jun; 97(6):2208-16. PubMed ID: 17879294
[TBL] [Abstract][Full Text] [Related]
16. G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol.
Qi R; Li YZ; Chen C; Cao YN; Yu MM; Xu L; He B; Jie X; Shen WW; Wang YN; van Dongen MA; Liu GQ; Banaszak Holl MM; Zhang Q; Ke X
J Control Release; 2015 Jul; 210():160-8. PubMed ID: 26003044
[TBL] [Abstract][Full Text] [Related]
17. Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)-block-poly(D,L)-lactic-co-glycolic acid (PEG-PLGA) nanoparticles for the treatment of schizophrenia.
Piazza J; Hoare T; Molinaro L; Terpstra K; Bhandari J; Selvaganapathy PR; Gupta B; Mishra RK
Eur J Pharm Biopharm; 2014 May; 87(1):30-9. PubMed ID: 24560967
[TBL] [Abstract][Full Text] [Related]
18. Performance evaluation of PAMAM dendrimer based simvastatin formulations.
Kulhari H; Pooja D; Prajapati SK; Chauhan AS
Int J Pharm; 2011 Feb; 405(1-2):203-9. PubMed ID: 21145960
[TBL] [Abstract][Full Text] [Related]
19. Intranasal delivery of antipsychotic drugs.
Katare YK; Piazza JE; Bhandari J; Daya RP; Akilan K; Simpson MJ; Hoare T; Mishra RK
Schizophr Res; 2017 Jun; 184():2-13. PubMed ID: 27913162
[TBL] [Abstract][Full Text] [Related]
20. Effects of tryptophan and valine administration on behavioral pharmacology of haloperidol.
Ali O; Haleem DJ; Saify ZS; Kamil N; Obaid R; Ahmed SW
Pak J Pharm Sci; 2005 Apr; 18(2):23-8. PubMed ID: 16431394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
